http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AstraZeneca (AZN) Presents Data on LYNPARZA (olaparib) Significantly Reduces the Risk of Disease Worsening or Death in Patients at ASCO Meetings
-
LYNPARZA™ (olaparib) Significantly Reduces the Risk of Disease Worsening or Death in Patients with BRCA-Mutated Metastatic Breast Cancer
-
AstraZeneca (AZN) Delivers New Data on Cancer Medicines at ASCO
-
AstraZeneca Delivers New Data on Expanding Portfolio of Cancer Medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
-
AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot
-
AstraZeneca (AZN) Announces BYDUREON EXSCEL Trial Meets Primary Safety Objective in Type-2 Diabetes Patients with Rage of CV Risk
-
BYDUREON EXSCEL Trial Meets Primary Safety Objective in Type-2 Diabetes Patients at Wide Range of Cardiovascular Risk
-
AstraZeneca (AZN) Says Results from Phase III ZONDA Trial Presented at ATS, Published in NEJM
-
Phase III ZONDA Trial for benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients
-
Pieris Pharma (PIRS), AstraZeneca (AZN) Announced Pact to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases
-
AstraZeneca (AZN) Confirms IMFINZI Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer
-
AstraZeneca’s IMFINZI™ (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer
-
AstraZeneca's Imfinzi (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients With Advanced Bladder Cancer
-
TAGRISSO® (osimertinib) Receives US FDA Full Approval
-
AstraZeneca (AZN) Announces New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result in Reduced Overall Costs
-
New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result in Reduced Overall Costs in Preterm Infants Born at 29-32 wGA Who Are Less Than Three Months of Age
-
AstraZeneca (AZN) Says FDA Accepted NDA for LYNPARZA
-
AstraZeneca Shares Progress on LYNPARZA™ (olaparib) Tablets in the US
-
AstraZeneca (AZN) CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death Versus Other Type-2 Diabetes Medication
-
AstraZeneca’s CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death versus Other Type-2 Diabetes Medicines
-
AstraZeneca (AZN) Reports LYNPARZA Phase III SOLO-2 Met Primary Endpoint in Relapsed Ovarian Cancer Patients
-
LYNPARZA™ (olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit in BRCA-Mutated Ovarian Cancer as Maintenance Therapy
-
AstraZeneca (AZN) Announces FDA Approval for Once-Daily QTERN for Type-2 Diabetes
-
FDA Approves Once-Daily QTERN® (Dapagliflozin and Saxagliptin) Tablets for Adults with Type-2 Diabetes
-
AstraZeneca (AZN) Says LYNPARZA Met Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
-
LYNPARZA™ (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
-
Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
-
Pfizer (PFE) Completes Acquisition of AstraZeneca's (AZN) Small Molecule Anti-Infective Business
-
AstraZeneca (AZN) Offers pre-Specificed Subgroup Analysis of FALCON Trial; PFS Seen as Largely Consistent
-
AstraZeneca Announces Subgroup Analysis from FALCON Trial Comparing FASLODEX® (fulvestrant) to ARIMIDEX® (anastrozole)
-
TAGRISSO® (osimertinib) Demonstrates Superiority over Chemotherapy in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
-
AstraZeneca (AZN), Acerta Announce Prelim. Acalabrutinib Phase 1/2 Data in CLL; Median PFS Not Yet Met
-
Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukemia
-
AstraZeneca (AZN) Announces Significant Results from SYMBICORT Phase 3 in Pediatric Asthma Patients
-
AstraZeneca Announces Study Results Show SYMBICORT Improves Lung Function in Pediatric Asthma Patients
-
AstraZeneca (AZN) Announces Data from Second-Season SENTINEL1 Study; Says Results Similar to Prior Season
-
New Data Shows Frequent ICU Admissions from Severe RSV Disease among Preterm Infants in the First Three Months of Life
-
AstraZeneca (AZN) Announces Significant PFS Data from LYNPARZA Phase III SOLO-2
-
LYNPARZATM (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit
-
Cancer Immunotherapy ETF Celebrates One-Year Anniversary
-
Pfizer (PFE) Enters Agreement to Acquire AstraZeneca's (AZN) Small Molecule Anti-Infective Business in ~$1.58B Deal
-
AstraZeneca Introduces AZhelps, an Innovative Savings and Support Program to Help Patients with Their Medicines
-
Ironwood Pharma (IRWD) Announces Closure of Lesinurad Transaction with AstraZeneca (AZN)
-
Top 10 News for 5/23 - 5/27: Computer Sciences to Acquire Key Enterprise Asset; Bayer Makes Run at Monsanto; Twitter has 'Character' Change
-
Advaxis (ADXS) Announces Completion of First Dose-Escalation for AXAL + Durvalumab Combo in HPV-Associated Cancers
-
Celgene (CELG), AstraZeneca (AZN) Initiative Durvalumab FUSION Program in Hematologic Disorders
-
Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology
-
Notable Mergers and Acquisitions 11/6: (BABA)/(YOKU) (AZN)/(ZSPH) (FNGN) (DIOD)/(PSEM) (NSR)
-
Market Wrap: Buffett Lands 'Whale' of A Deal; Google Announces Major Restructuring; Twitter Gains on Insider Trades
-
Pre-Open Stock Movers 08/10: (AQXP) (VLTC) (INO) (PCP) Higher; (SYN) (JD) (FCX) Lower (more...)

